U.S. healthcare providers need improved access to interventions known to prevent common causes of cancer death so the country can achieve President Joe Biden’s Cancer Moonshot initiative goal of reducing the cancer death rate by at least 50% over the next 25 years, according to a National Institutes of health study published in April 2023 that was led by National Cancer Institute researchers.

Recharting the trajectory of cancer in the United States requires involvement from everyone—government and private investors, researchers, clinicians, and people with cancer, their caregivers, and advocates, the National Cancer Institute said in April 2023 as it launched the National Cancer Plan. The plan supports the Cancer Moonshot initiative and “aligns broad societal engagement and focuses on critical needs to end cancer as we know it.”

Recognizing the 60th anniversary of President John F. Kennedy’s historic moonshot speech, on September 12, 2022, President Joe Biden delivered an update on his relaunched Cancer Moonshot Initiative and progress made on its moonshot goal of “ending cancer as we know it.”

To support the objectives of President Joe Biden’s relaunched Cancer Moonshot initiative, the Centers for Disease Control and Prevention awarded $215 million to three national cancer programs in June 2022. The funds are part of a $1.1 billion investment in cancer prevention and control.

With broad backgrounds in oncology genetics, immunology, and disparities, President Joe Biden’s three July 2022 appointments to the Cancer Cabinet will help guide the United States on opportunities to reduce cancer’s barriers and burden for underserved populations.

Monica Bertagnolli, MD, will serve as the next—and first woman—director of the National Cancer Institute. President Joe Biden announced his intent to make the appointment in August 2022.

In a clarion call for action seven years ago, President Barack Obama unveiled the Cancer Moonshot during his last State of the Union address. In that speech, Obama recalled, “Last year, Vice President Joe Biden said that with a new moonshot, America can cure cancer. Tonight, I’m announcing a new national effort to get it done. And I’m putting Joe in charge of Mission Control.”

Driven by the reignited Cancer Moonshot, the National Cancer Institute (NCI) hosted a virtual roundtable discussion on the possibilities and challenges of increasing clinical trial accrual in May 2022.  

The U.S. Food and Drug Administration (FDA) proposed two product standards in April 2022 aimed at banning flavored tobacco and menthol products. According to FDA, the proposed product standard would “reduce the appeal of cigarettes, particularly to youth and young adults, and thereby decrease the likelihood that nonusers who would otherwise experiment with menthol cigarettes would progress to regular smoking.” 

Building support for the Cancer Moonshot reignition, President Joe Biden appointed temporary leaders to streamline the White House Office of Science and Technology Policy’s (OSTP’s) agenda of creating the Advanced Research Projects Agency for Health. Alondra Nelson, PhD, will serve as OSTP director and Francis Collins, MD, PhD, as science advisor to the president and co-chair of the President’s Council of Advisors on Science and Technology until permanent leaders are in place. Biden made the appointments in February 2022 after Eric Lander, his science advisor who also served as OSTP director, announced his resignation from the role.

The explosion of immunotherapy in your practice? You can thank the Cancer Moonshot. New discoveries in oncodrivers for childhood cancers? Thank the Moonshot again. You can also thank it for better cancer prevention and screening strategies, attention to patient-centered care, and interprofessional collaboration among oncology scientists and clinicians.

Driving “cancer research that spans the continuum from basic science to survivorship” and taking advantage of the “incredible opportunity to greatly reduce the impact of cancer on people’s lives and end cancer as we know it” takes an investment, the National Cancer Institute (NCI) acknowledged in its proposed budget for the 2023 fiscal year. However, fully funding “cutting-edge research, infrastructure, and training needed to harness these opportunities allows researchers better understand how to prevent and treat cancer.”

My area of research focus is adults with primary central nervous system (CNS) tumors, which represent less than 2% of all diagnosed cancers. Because of the cancers’ rarity, access to diagnosed patients for research initiatives is limited. My team’s program, NCI-CONNECT, a part of the Rare Tumor Patient Engagement Network supported by the Cancer Moonshot, is advancing our understanding of adults with rare CNS cancers by establishing patient-advocacy-provider partnerships and networks to improve care and treatment approaches.

When the Obama administration announced the National Cancer Moonshot in January 2016, its goal was to invest $1 billion in cancer research to make a decade’s worth of discoveries in just five years. The funding was distributed across the National Institutes of Health, U.S. Food and Drug Administration, Department of Defense, and Department of Veterans Affairs to propel the Moonshot forward.

In honor of World Cancer Day on February 4, 2021, First Lady Jill Biden, EdD, took a virtual tour of the National Institutes of Health’s (NIH's) National Cancer Institute (NCI) and met with NIH Director Francis Collins, MD, PhD, and NCI Director Ned Sharpless, MD, to discuss advancements in cancer research, the steady decline in cancer mortality, and cancer-related legislation, among other topics. 
 

During his final State of the Union address in January 2016, former President Barack Obama appointed Joe Biden the lead on a new initiative: the National Cancer Moonshot. The goal was to find treatments, cures, and more understanding about cancer—a decade’s worth of progress in just five years. 

As part of its focus to dismantle the 2010 healthcare law, the GOP repealed the Affordable Care Act individual mandate in 2017. Republican state attorneys general then challenged the law’s constitutionality in a series of lower court cases, and the most recent has been lingering in federal courts for more than a year. On March 2, the Supreme Court agreed to take up the issue, marking the third time the law will be heard at the highest court in the country.  

As the 2020 presidential campaign kicks into high gear, the much-anticipated candidacy of former Vice President Joe Biden was announced. Biden, along with his wife Jill, had to make the necessary legal adjustments to cut ties with their formal involvement in the Biden Foundation, including a number of cancer-related projects. The Bidens made the move to eliminate any potential conflicts of interest with a presidential run.

The new 116th Congress has settled in, and a clearer picture of the diverse freshman class has come to light. In this case, nursing is present and accounted for among incoming congressional representatives. Lauren Underwood (D-IL) is an RN who ran on her support for health care, specifically to protect those with pre-existing conditions. She’s already a co-chair of the Congressional Nursing Caucus and has signed on to Title VIII nursing reauthorization legislation—something ONS has continually championed. Representative Eddie Bernice Johnson (D-TX)—the first nurse ever elected to Congress—is entering her 13th term in the chamber and continues to offer a veteran nursing presence on the hill.

Still a popular program throughout the government, the Cancer Moonshot Initiative challenged the United States to meet goals to accelerate cancer research progress, encourage collaboration in finding treatments and cures, and to improve data sharing to make a decade’s progress in half the time. Through NIH’s Moonshot Blue Ribbon Panel and the 2016 passage of the 21st Century Cures Act—allocating $1.8 billion over seven years for Moonshot—the initiative is moving out of planning and into the research phase.

As a continuation of the National Cancer Moonshot legacy, the Biden Cancer Initiative (BCI) announced its inaugural roster of FIERCE Award recipients, naming 10 transformative healthcare professionals and institutions who have driven change and positively impacted the lives of their patients with cancer. For her work as an oncology nurse navigator and her accomplishments in patient navigation, ONS member Cynthia Cantril, RN, OCN^®, CBCN^®, MPH, was named one of the BCI’s FIERCE Award recipients at the Biden Cancer Summit Welcome Reception in Washington, DC, on September 20, 2018.

The Biden Cancer Summit was held in Washington, DC, on September 21, 2018. The day-long event was filled with cancer-related educational sessions—some hosted by ONS leadership—discussing ways to move cancer research and care forward. Formerly dubbed the National Cancer Moonshot Initiative, the country-wide effort to make a quantum leap in cancer care has evolved in into the Biden Cancer Initiative (BCI). BCI’s ongoing work will continue to break down barriers and help providers and researchers overcome obstacles as they work toward progress in cancer care.

Like all great adventures, it began as an idea. What if the United States could make huge advancements in the fight against cancer in a short amount of time? How could that be accomplished? What are the metrics? How much would it cost? Who could direct such an effort? 

As the Affordable Care Act is challenged in court, 12 Republican Senators signed a letter insisting that pre-existing conditions be covered in any new healthcare laws moving forward. Despite initial praise for the GOP, many patient advocacy groups, including the American Cancer Society Cancer Action Network, have voiced concerns about the efforts being far too little and far too late. On September 4, 2018, more than 25 patient advocacy groups came together and released a statement condemning a recent Republican bill stating it didn’t provide enough protections for pre-existing conditions, compared to what’s currently covered under the ACA. The advocacy groups noted the bill's outlying weaknesses and pushed for stronger reassurances.

In coffee shops around the country, between clicking cups and grinding coffee beans, former second lady of the United States, Jill Biden, EdD, is quietly gathering small groups of oncology nurses, care coordinators, social workers, and family members who support patients with cancer to discuss the obstacles facing caregivers throughout the cancer journey. As part of the Biden Cancer Initiative’s (BCI’s) continued work to improve oncology care, this coterie of caregivers is heralding the trials and triumphs that come with addressing the physical, social, emotional, and spiritual needs of patients with cancer.

ONS President Susan Schneider, PhD, RN, AOCN^®, FAAN, was appointed to the Biden Cancer Initiative board of directors, among other experts in health care, business, finance, and technology. The Cancer Initiative also named ONS Chief Executive Officer Brenda Nevidjon MSN, RN, FAAN, to its advisory committee, comprised of 25 other experts aiming to transform the way cancer is detected, diagnosed, and treated by implementing new solutions to complex healthcare problems.  

Since its initial announcement, the National Cancer Moonshot Initiative—dubbed the Biden Cancer Initiative—has captivated the scientific, patient advocacy, and provider communities with possibilities for advancements in cancer treatments and cures. The cancer moonshot continues to maintain bipartisan support, as all involved are committed to making a decade’s worth of progress in just half the time.

The future of oncology care hinges on the implementation of new sciences, the collaboration of researchers, and timeliness with which healthcare professionals can integrate change into practice, according to a new report released by Lancet Oncology.

In one bold declaration during his final State of the Union Address in 2016, President Barack Obama raised our hopes to a singular goal—ending cancer as we know it—as he announced the National Cancer Moonshot Initiative, now called the Biden Cancer Initiative. Grounded in real research with tangible results, the intent was not even that daring: it was more realistic. Eradicating cancer, now understood to be many different aspects of the same disease, in five years was unlikely, but rather the goal was to achieve in five years what previously would take a decade.

“Congress is working together on a nonpartisan issue that will have a profound effect on the lives of all Americans. H.R. 6, the 21st Century Cures Act, will bring our health care innovation infrastructure into the 21st Century, delivering hope for patients and loved ones and providing necessary resources to researchers to continue their efforts to uncover the next generation of cures and treatments,” Chairman Fred Upton (R-MI) and Representative Diana DeGette (D-CO) discussed their vision for the 21st Century Cures initiative in April 2014.

The National Institutes of Health (NIH) recently released the Annual Report to the Nation on the Status of Cancer, 1975–2014. According to the report, cancer death rates fell for 11 of the 16 most common cancers in men and 13 of the 16 most common cancers in women. Death rates fell for female breast cancer, lung cancer, colorectal cancer, and prostate cancers, among others. The report also notes that incidences of cancer decreased in men but plateaued for women in the same time period.

To a crowd of more than 1,300 attendees at the South by Southwest Conference (SXSW) in Austin, TX, on March 12, 2017, former Vice President Joe Biden announced that the Biden Foundation, his new nonprofit organization, would be continuing the work of the National Cancer Moonshot Initiative, which he led during his final year as vice president.

In collaboration with the former President Obama’s health policy team and the Cancer Moonshot, myself and several other members of ONS were invited to attend a community oncology event as part of the White House’s Making Health Care Better series.  The event, “Addressing the Cancer Challenge: Progress in Research, Prevention, Coverage, and Quality,” took place at the White House complex on January 11, 2017. It was by invitation only from the White House Cancer Moonshot Task Force.

After the dust settled from the presidential election, Congress returned to Washington to complete some remaining legislative work before the new year. Among the newly approve legislation, the 21st Century Cures Act was passed, and it aims to have major implications for expanding oncology research in the coming months and years.

Cancer Moonshot Summit Kicked Off in DC

June 29, 2016, marked the first official Cancer Moonshot Summit in Washington, DC. Hosted by Vice President Joe Biden, the summit brought together the nation’s leading oncology experts, researchers, healthcare professionals, survivors, private industry professionals and more. Many from the cancer community convened in DC with the hopes of advancing progress towards a cure.